Eledon Pharmaceuticals (NASDAQ: ELDN) announced updated results from its ongoing Phase 1b trial evaluating tegoprubart for preventing organ rejection in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE